Bladder cancer is a common cancer in men and woman. The risk of developing bladder cancer is approximately three times higher in men than in women and the risk increases with smoking and with age.

One of the most common symptoms of bladder cancer is the presence of blood in urine (hematuria). After presenting with hematuria, the patient is normally referred to urologist, either private or hospital based for further investigations

More than 70% of cases are non-muscle invasive bladder cancers, but many patients progress to muscle invasive bladder cancer or metastatic disease. To improve the prognosis of bladder cancer, employing effective methods for early detection and regular follow-up is vital for the patient.

Cystoscopy and urine cytology are the most common methods for detection and assessment of recurrence of bladder cancer. Cystoscopy may cause pain and discomfort in patients and in cases with small tumours or carcinoma in situ, a diagnosis is not readily performed. Urine cytology, a non-invasive urine test is often used as an adjunct to cystoscopy. However, even if cytology has the advantage of high specificity, its sensitivity may vary considerably.

UBC® is a non-invasive bladder cancer test available in different testing platforms.